Prahlad Parajuli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Prahlad Parajuli has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Aroma Naeem
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, USA
2 shared publicationsHirva Mamdani
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
2 shared publicationsLisa Polin
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
2 shared publicationsManohar Ratnam
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
2 shared publicationsRayna Rosati
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
2 shared publicationsSijana Dzinic
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
2 shared publications
Latest Publications
- Open Access
Poikiloderma with Neutropenia, Clericuzio Type (OMIM #604173): From USB1 RNA Biology to a Candidate Model of Compartmentalized Cyclic Nucleotide Signaling
Poikiloderma with neutropenia, Clericuzio type (PN; OMIM #604173), is a rare autosomal recessive genodermatosis caused by biallelic loss-of-function variants in U6 snRNA Biogenesis 1 (USB1), with approximately 100 molecularly confirmed cases. Beyond the defining post-inflammatory poikiloderma and non-cyclic neutropenia, affected individuals show recurrent sinopulmonary infection, impaired wound healing, tendon contractures, and primary gonadal failure in males. USB1 is a 2H-superfamily 3′ to 5′ exoribonuclease that removes oligoadenylate tails added by Poly(A) polymerase associated protein 5 (PAPD5) and PAPD7; its loss destabilizes guide-strand microRNAs and blocks the emergence of CD45+ hematopoietic progenitors. Splicing is not measurably disturbed in patient cells, so the earlier splicing-centered account requires revision. Drawing on previously unpublished endocrine, neurologic and imaging data from two affected brothers, we develop a candidate model in which the microRNA lesion reaches cyclic nucleotide signaling by two routes: de-repression of phosphodiesterase E3B (PDE3B) after loss of miR-142-5p, and loss of a perinuclear and Golgi cyclic AMP compartment after coordinate reduction in A-kinase anchoring protein 6 (AKAP6) and PDE4D interacting protein (PDE4DIP). We state where the model is supported, where it conflicts with published effects, and what would refute it, arguing for compartment-restricted dysregulation rather than global deficiency. PAPD5/7 inhibition, leading to repression of PDE3B, is closest to the causal lesion, but its on-target neurotoxicity makes it an experimental tool rather than a candidate drug.
Open AccessPoikiloderma with Neutropenia, Clericuzio Type (OMIM #604173): From USB1 RNA Biology to a Candidate Model of Compartmentalized Cyclic Nucleotide Signaling
Poikiloderma with neutropenia, Clericuzio type (PN; OMIM #604173), is a rare autosomal recessive genodermatosis caused by biallelic loss-of-function variants in U6 snRNA Biogenesis 1 (USB1), with approximately 100 molecularly confirmed cases. Beyond the defining post-inflammatory poikiloderma and non-cyclic neutropenia, affected individuals show recurrent sinopulmonary infection, impaired wound healing, tendon contractures, and primary gonadal failure in males. USB1 is a 2H-superfamily 3′ to 5′ exoribonuclease that removes oligoadenylate tails added by Poly(A) polymerase associated protein 5 (PAPD5) and PAPD7; its loss destabilizes guide-strand microRNAs and blocks the emergence of CD45+ hematopoietic progenitors. Splicing is not measurably disturbed in patient cells, so the earlier splicing-centered account requires revision. Drawing on previously unpublished endocrine, neurologic and imaging data from two affected brothers, we develop a candidate model in which the microRNA lesion reaches cyclic nucleotide signaling by two routes: de-repression of phosphodiesterase E3B (PDE3B) after loss of miR-142-5p, and loss of a perinuclear and Golgi cyclic AMP compartment after coordinate reduction in A-kinase anchoring protein 6 (AKAP6) and PDE4D interacting protein (PDE4DIP). We state where the model is supported, where it conflicts with published effects, and what would refute it, arguing for compartment-restricted dysregulation rather than global deficiency. PAPD5/7 inhibition, leading to repression of PDE3B, is closest to the causal lesion, but its on-target neurotoxicity makes it an experimental tool rather than a candidate drug.
- 17 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1574-1585
Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel‐like factor 1 (KLF‐1)‐E325K‐associated congenital dyserythropoietic anaemia (CDA‐IV)
Summary: A heterozygous Kruppel‐like factor 1 (KLF1) E325K mutation causes a severe form of congenital dyserythropoietic anaemia (CDA), designated CDA‐IV (Online Mendelian Inheritence in Man, OMIM 613673), a rare disease with only 15 cases known. In addition to haemolytic anaemia, manifest often at birth, four of seven (57%) of 46,XY children with KLF1 E325K mutation exhibit a range of dysmorphic external genitalia including 46,XY complete sex reversal (2/7 or 28.5%). No genital abnormalities were reported in a boy with double heterozygous KLF1 null mutations, suggesting that the KLF1 E325K variant causes, in addition to its negative impacts on erythroid differentiation, disruptions in male sex differentiation. Our studies suggest a role for a cooperative effect of concurrent ‘non‐pathogenic’ polymorphisms in multiple genes associated with disorders of sex differentiation (DSD), notably fibroblast growth factor 9 ( FGF9 ), whose expression was decreased in the gonads and peripheral blood in the case described here. We propose that the combined loss of FGF9 and CD44 (a target for CDA‐IV KLF1) resulted FGF9 signalling loss and likely caused 46,XY sex reversal. Our studies also suggest that whole‐blood gene expression studies in the proband/parent triad may provide critical clues in evaluating children with DSD, the cause of which remains undiagnosed in many cases.
- 17 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1574-1585
Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel‐like factor 1 (KLF‐1)‐E325K‐associated congenital dyserythropoietic anaemia (CDA‐IV)
Summary: A heterozygous Kruppel‐like factor 1 (KLF1) E325K mutation causes a severe form of congenital dyserythropoietic anaemia (CDA), designated CDA‐IV (Online Mendelian Inheritence in Man, OMIM 613673), a rare disease with only 15 cases known. In addition to haemolytic anaemia, manifest often at birth, four of seven (57%) of 46,XY children with KLF1 E325K mutation exhibit a range of dysmorphic external genitalia including 46,XY complete sex reversal (2/7 or 28.5%). No genital abnormalities were reported in a boy with double heterozygous KLF1 null mutations, suggesting that the KLF1 E325K variant causes, in addition to its negative impacts on erythroid differentiation, disruptions in male sex differentiation. Our studies suggest a role for a cooperative effect of concurrent ‘non‐pathogenic’ polymorphisms in multiple genes associated with disorders of sex differentiation (DSD), notably fibroblast growth factor 9 ( FGF9 ), whose expression was decreased in the gonads and peripheral blood in the case described here. We propose that the combined loss of FGF9 and CD44 (a target for CDA‐IV KLF1) resulted FGF9 signalling loss and likely caused 46,XY sex reversal. Our studies also suggest that whole‐blood gene expression studies in the proband/parent triad may provide critical clues in evaluating children with DSD, the cause of which remains undiagnosed in many cases.
- 11 December 2024
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 37 (4) , 116-117
Evaluation of Immune Deficiency Disorders in the Clinic—A Case for Routine Testing of Monocyte Subsets with CD14 and CD16 Expression
- 11 December 2024
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 37 (4) , 116-117
Evaluation of Immune Deficiency Disorders in the Clinic—A Case for Routine Testing of Monocyte Subsets with CD14 and CD16 Expression
- 25 November 2022
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (5) , 1273-1284
Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes
There is a need to improve response rates of immunotherapies in lung adenocarcinoma (AC). Extended (7–14 days) treatment of high glucocorticoid receptor (GR) expressing lung AC cells with dexamethasone (Dex) induces an irreversible senescence phenotype through chronic induction of p27. As the senescence-associated secretory phenotype (SASP) may have either tumor supporting or antitumor immunomodulatory effects, it was interest to examine the effects of Dex-induced senescence of lung AC cells on immune cells. Dex-induced senescence resulted in sustained production of CCL2, CCL4, CXCL1 and CXCL2, both in vitro and in vivo. After Dex withdrawal, secretion of these chemokines by the senescent cells attracted peripheral blood monocytes, T-cells, and NK cells. Following treatment with Dex-induced SASP protein(s), the peripheral blood lymphocytes exhibited higher cell count and tumor cytolytic activity along with enhanced Ki67 and perforin expression in T and NK cells. This cytolytic activity was partially attributed to NKG2D, which was upregulated in NK cells by SASP while its ligand MICA/B was upregulated in the senescent cells. Enhanced infiltrations of T and NK cells were observed in human lung AC xenografts in humanized NSG mice, following treatment with Dex. The findings substantiate the idea that induction of irreversible senescence in high-GR expressing subpopulations of lung AC tumors using Dex pretreatment enhances tumor immune infiltration and may subsequently improve the clinical outcome of current immunotherapies.
- 25 November 2022
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (5) , 1273-1284
Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes
There is a need to improve response rates of immunotherapies in lung adenocarcinoma (AC). Extended (7–14 days) treatment of high glucocorticoid receptor (GR) expressing lung AC cells with dexamethasone (Dex) induces an irreversible senescence phenotype through chronic induction of p27. As the senescence-associated secretory phenotype (SASP) may have either tumor supporting or antitumor immunomodulatory effects, it was interest to examine the effects of Dex-induced senescence of lung AC cells on immune cells. Dex-induced senescence resulted in sustained production of CCL2, CCL4, CXCL1 and CXCL2, both in vitro and in vivo. After Dex withdrawal, secretion of these chemokines by the senescent cells attracted peripheral blood monocytes, T-cells, and NK cells. Following treatment with Dex-induced SASP protein(s), the peripheral blood lymphocytes exhibited higher cell count and tumor cytolytic activity along with enhanced Ki67 and perforin expression in T and NK cells. This cytolytic activity was partially attributed to NKG2D, which was upregulated in NK cells by SASP while its ligand MICA/B was upregulated in the senescent cells. Enhanced infiltrations of T and NK cells were observed in human lung AC xenografts in humanized NSG mice, following treatment with Dex. The findings substantiate the idea that induction of irreversible senescence in high-GR expressing subpopulations of lung AC tumors using Dex pretreatment enhances tumor immune infiltration and may subsequently improve the clinical outcome of current immunotherapies.
- Open Access
- 26 July 2022
- Published by Springer Nature in Research Square
Senescence Associated Secretory Proteins Induced in Lung Adenocarcinoma by Extended Treatment with Dexamethasone Enhance Migration and Activation of Lymphocytes
There is a need to improve response rates of immunotherapies in lung adenocarcinoma (AC). Extended (7–14 day) treatment of high glucocorticoid receptor (GR) expressing lung AC cells with dexamethasone (Dex) induces an irreversible senescence phenotype through chronic induction of p27. As the senescence associated secretory phenotype (SASP) may have either tumor supporting or antitumor immunomodulatory effects, it was of interest to examine the effects of Dex-induced senescence of lung AC cells on immune cells. Dex-induced senescence resulted in sustained production of CCL2, CCL4, CXCL1 and CXCL2, both in vitro and in vivo. After Dex withdrawal, secretion of these chemokines by the senescent cells attracted peripheral blood monocytes, T-cells, and NK cells. Following treatment with Dex-induced SASP protein(s), the peripheral blood lymphocytes exhibited higher cell count and tumor cytolytic activity along with enhanced Ki67 and perforin expression in T and NK cells. This cytolytic activity was partially attributed to NKG2D, which was upregulated in NK cells by SASP while its ligand MICA/B was upregulated in the senescent cells. Enhanced infiltrations of T ad NK cells were observed in human lung AC xenografts in humanized NSG mice, following treatment with Dex. The findings substantiate the idea that induction of irreversible senescence in high-GR expressing subpopulations of lung AC tumors using Dex pretreatment enhances tumor immune infiltration and may subsequently improve the clinical outcome of current immunotherapies.
- 26 July 2022
- Published by Springer Nature in Research Square
Open AccessSenescence Associated Secretory Proteins Induced in Lung Adenocarcinoma by Extended Treatment with Dexamethasone Enhance Migration and Activation of Lymphocytes
There is a need to improve response rates of immunotherapies in lung adenocarcinoma (AC). Extended (7–14 day) treatment of high glucocorticoid receptor (GR) expressing lung AC cells with dexamethasone (Dex) induces an irreversible senescence phenotype through chronic induction of p27. As the senescence associated secretory phenotype (SASP) may have either tumor supporting or antitumor immunomodulatory effects, it was of interest to examine the effects of Dex-induced senescence of lung AC cells on immune cells. Dex-induced senescence resulted in sustained production of CCL2, CCL4, CXCL1 and CXCL2, both in vitro and in vivo. After Dex withdrawal, secretion of these chemokines by the senescent cells attracted peripheral blood monocytes, T-cells, and NK cells. Following treatment with Dex-induced SASP protein(s), the peripheral blood lymphocytes exhibited higher cell count and tumor cytolytic activity along with enhanced Ki67 and perforin expression in T and NK cells. This cytolytic activity was partially attributed to NKG2D, which was upregulated in NK cells by SASP while its ligand MICA/B was upregulated in the senescent cells. Enhanced infiltrations of T ad NK cells were observed in human lung AC xenografts in humanized NSG mice, following treatment with Dex. The findings substantiate the idea that induction of irreversible senescence in high-GR expressing subpopulations of lung AC tumors using Dex pretreatment enhances tumor immune infiltration and may subsequently improve the clinical outcome of current immunotherapies.